ArticleJAMA network open2026
Automated Speech-Based Modeling of Item-Level Symptom Severity in Schizophrenia.
Article in JAMA network open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Speech carries subtle indicators of current mental state, a phenomenon routinely used in psychiatric assessment. Despite its potential, quantitative speech analysis is not yet integrated into clinical care. Objective: To identify which features of naturalistic speech are associated with concurrent variation in symptom severity in patients with psychotic disorders. Design, Setting, and Participants: This longitudinal, multicenter cohort study was conducted in the Netherlands (June 7, 2017, to July 31, 2025) in adult patients (aged ≥18 years) with schizophrenia spectrum disorders who completed repeated clinical and speech assessments for up to 8 years. Findings were replicated in a longitudinal cohort from the US (March 1, 2021, to December 1, 2022). Main Outcomes and Measures: Individual symptom severity was measured using the Positive and Negative Syndrome Scale (PANSS) (Dutch cohort) or the Brief Psychiatric Rating Scale (US cohort). Speech samples were converted into interpretable artificial intelligence-derived voice and text features, reduced using principal component analysis. Associations were estimated using linear mixed models adjusted for demographic characteristics and time point. Estimative accuracy was quantified using mean absolute error (MAE) and R2. Results: In the Dutch cohort, 773 speech recordings from 356 participants (mean [SD] age, 30.4 [10.3] years; 257 male [72.2%]) were analyzed, and in the US cohort, 165 speech recordings from 72 participants (mean [SD] age, 26.4 [5.2] years; 46 male [64.8%]) were analyzed. In the Dutch cohort, speech-based models detected individual psychotic symptoms with clinically meaningful accuracy, with an item-level MAE of less than 1 point (scale, 1-7), comparable to the 1-point agreement margin used in PANSS rater training. Models were associated with PANSS positive and negative subscale scores, with MAE of 2.85 and 3.22, explaining 13.4% and 17.8% of the variance, respectively, and well below the 20% threshold used to flag unreliable PANSS ratings. In the US replication cohort, Brief Psychiatric Rating Scale thought disturbance and withdrawal scores were associated with similar MAEs (3.0 and 2.4, respectively), explaining 31.0% and 21.5% of the variance. In the Dutch cohort, negative symptoms were associated with more reduced speech output (estimate, 2.46 [95% CI, 1.05-3.88]) and flatter acoustic profiles (estimate, 0.29 [95% CI, 0.10-0.48]), whereas positive symptoms were marked by longer utterances (estimate, 1.18 [95% CI, 0.08-2.29]) and altered discourse organization (estimate, -0.25 [95% CI, -0.48 to -0.02]). Conclusions and Relevance: This cohort study of individuals with schizophrenia found that psychotic symptoms left specific, interpretable signatures in naturalistic speech that could be quantified, tracked longitudinally, and replicated across cohorts. Speech-based modeling achieved clinically meaningful, symptom-level estimations, providing a solid basis for scalable, low-burden tools for real-time monitoring in psychosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.